SCHEDULE: Madrigal Pharma Director Amends 7.8% Stake Disclosure

Dr. Rebecca Taub, a director at Madrigal Pharmaceuticals, filed an amended Schedule 13D to update her beneficial ownership, now totaling 7.8% of common stock, and disclose recent share transactions.

Summary

• Dr. Rebecca Taub, Senior Scientific and Medical Advisor and Board member of Madrigal Pharmaceuticals, Inc., filed an Amendment No. 2 to her Schedule 13D.
• The amendment updates her beneficial ownership to an aggregate of 1,814,831 shares of Common Stock, representing 7.8% of the class.
• This beneficial ownership is based on 22,711,420 shares outstanding as of October 30, 2025.
• The reported amount includes shares held by Dr. Taub, stock options and restricted stock units exercisable/vesting within 60 days for both Dr. Taub and her spouse, and shares held by SQN, LLC, where Dr. Taub is a managing member.
• The amendment clarifies that the Original Statement inadvertently excluded shares beneficially owned by Dr. Taub's spouse.
• Dr. Taub disclaims beneficial ownership of Common Stock owned by SQN, LLC and her spouse.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and insider transactions. While insider sales occurred, they are not significant enough to drastically alter the overall sentiment without further context on the reasons for sale. The amendment primarily corrects a previous oversight.

Positives

• The filing provides increased transparency regarding the beneficial ownership structure of a key insider and her related parties.
• Dr. Taub continues to serve as Senior Scientific and Medical Advisor and a member of the Board of Directors, indicating continued involvement in the company's strategic direction.

Negatives

• Dr. Taub and her spouse collectively sold 43,450 shares of common stock on the open market on December 10, 2025, which could be perceived as a reduction in insider confidence, although it's a small percentage of their total holdings.

Risks

• Insider sales, even if for personal reasons, can sometimes be interpreted by the market as a signal of reduced confidence in the company's short-term prospects, potentially leading to negative share price movement.

Future Outlook

The filing does not provide specific forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing instead on beneficial ownership disclosure.

Industry Context

This Schedule 13D amendment is a routine regulatory disclosure of insider ownership changes and does not directly relate to broader industry trends or competitive landscape analysis. It provides transparency into a key insider's stake in a pharmaceutical company.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure of beneficial ownership and does not contain information that allows for a direct comparison of company results or projects to global industry benchmarks or specific comparable companies.

Management Changes

Related Party Transactions

• Dr. Taub's spouse holds shares, stock options, and restricted stock units, and engaged in open market sales of Common Stock.
• Dr. Taub is a managing member of SQN, LLC, which holds Common Stock, and she may be deemed to share voting and investment power over these shares.

Stakeholder Impact

• Shareholders: Provides updated transparency on a significant insider's holdings and recent transactions, which can inform investment decisions. The insider sales might be viewed with caution by some investors.

Next Steps

• The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price in the reported range.

Key Dates

Recommendation

This filing is primarily a regulatory update correcting previous disclosures and reporting routine insider transactions. While insider sales occurred, they are not substantial enough to warrant a 'sell' recommendation, nor is there new information to suggest a 'buy' or 'strong buy'. The continued involvement of Dr. Taub as a Senior Scientific and Medical Advisor and Board member suggests ongoing commitment. Investors should 'hold' and monitor future company developments and insider activity for more definitive signals.

Keywords

Madrigal Pharmaceuticals, Rebecca Taub, Schedule 13D, Beneficial Ownership, Insider Trading, Common Stock, Equity Awards, Pharmaceuticals, Corporate Governance, SEC Filing